It is made available under a CC-BY 4.0 International license .

1	Clinical validation of novel second-trimester preterm preeclampsia risk predictors combining clinical
2	variables and serum protein biomarkers
3	
4	Louise C. LAURENT, MD, PhD <sup>1*</sup> , George R. SAADE, MD <sup>2</sup> , Glenn R. MARKENSON, MD <sup>3</sup> , Kent D. HEYBORNE,
5	MD <sup>4</sup> , Corina N. SCHOEN, MD <sup>5</sup> , Jason K. BAXTER, MD <sup>6</sup> , Sherri A. LONGO, MD <sup>7</sup> , Leonardo M. PEREIRA,
6	MD <sup>8</sup> , Emily J. SU, MD <sup>9</sup> , Matthew K. HOFFMAN, MD <sup>10</sup> , Garrett K. LAM, MD <sup>11</sup> , Angela C. FOX, MS <sup>12</sup> , Ashoka
7	D. POLPITIYA, D Sc <sup>12</sup> , Md. Bahadur BADSHA, PhD <sup>12</sup> , Tracey C. FLEISCHER, PhD <sup>12</sup> , Thomas J. GARITE, MD <sup>12</sup> ,
8	J. Jay BONIFACE, PhD <sup>12</sup> , Paul E. KEARNEY, PhD <sup>12</sup>
9	
10	<sup>1</sup> Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego,
11	La Jolla, CA
12	<sup>2</sup> Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA
13	<sup>3</sup> Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA
14	<sup>4</sup> Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO, and
15	Department of Obstetrics and Gynecology, University of Colorado Denver, Aurora, CO
16	<sup>5</sup> Department of Obstetrics and Gynecology, University of Massachusetts-Baystate, Springfield, MA
17	<sup>6</sup> Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson
18	University, Philadelphia, PA
19	<sup>7</sup> Department of Obstetrics and Gynecology, Ochsner Health, New Orleans, LA
20	<sup>8</sup> Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR
21	<sup>9</sup> Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO
22	<sup>10</sup> Department of Obstetrics and Gynecology, ChristianaCare Health System, Wilmington DE
23	<sup>11</sup> Regional Obstetrical Consultants, Chattanooga, TN; Department of Obstetrics & Gynecology,
24	University of Tennessee Health Science Center and College of Medicine, Chattanooga, TN

It is made available under a CC-BY 4.0 International license .

- 25 <sup>12</sup>Sera Prognostics, Inc., Salt Lake City, UT
- 26
- 27 \*Corresponding Author
- 28 Louise C. LAURENT, MD, PhD
- 29 Professor
- 30 Co-Chair, Center for OB/GYN Research Innovation
- 31 Department of Obstetrics, Gynecology, and Reproductive Sciences
- 32 Division of Maternal Fetal Medicine
- 33 The Sanford Consortium for Regenerative Medicine
- 34 University of California, San Diego
- 35 2880 Torrey Pines Scenic Dr.
- 36 La Jolla, CA 92037-0695
- 37 Phone: 858-246-1405
- 38 FAX: 858-534-8329
- 39 <u>llaurent@ucsd.edu</u>
- 40
- 41 **Financial support**
- 42 Financial support for the study was provided by Sera Prognostics, Inc. The sponsor funded the study,
- 43 generated biomarker data and discovered and blindly validated the predictors.
- 44
- 45 Short title
- 46 Proteomic biomarker risk predictors for preterm preeclampsia
- 47
- 48 Acknowledgments

It is made available under a CC-BY 4.0 International license .

49	Study funding was provided by Sera Prognostics, Inc. Jennifer Logan, PhD, an employee of Sera
50	Prognostics, Inc., contributed to the writing of this article. Babak Shahbaba, PhD (University of California
51	Irvine), conducted independent validation hypothesis testing. The authors wish to acknowledge the
52	following co-investigators on the original PAPR and/or TREETOP studies: Kim A. Boggess, MD (University
53	of North Carolina School of Medicine); Dean V. Coonrod, MD (University of Arizona College of Medicine);
54	Larry M. Cousins, MD (San Diego Perinatal Center; Rady Children's Specialists of San Diego); Amy H.
55	Crockett, MD (University of South Carolina School of Medicine Greenville and Prisma Health-Upstate);
56	M. Sean Esplin, MD (Intermountain Healthcare); William A. Grobman, MD, MBA (The Ohio State
57	University Wexner Medical Center); David M. Haas, MD (Indiana University School of Medicine); Angela
58	F. Hawk, MD (Regional Obstetrical Consultants); Jay D. Iams, MD (The Ohio State University Wexner
59	Medical Center); Carol A. Major, MD (University of California Irvine School of Medicine); Scott A.
60	Sullivan, MD (Medical University of South Carolina); and Sarahn M. Wheeler, MD (Duke University
61	School of Medicine). The authors also thank the study coordinators and research personnel at the study
62	sites, the clinical study participants, and the Sera Prognostics, Inc. research and development, clinical
63	laboratory and clinical operations teams.
64	
65	Preprint
66	A preprint of this manuscript has been posted at
67	https://www.medrxiv.org/content/10.1101/2022.12.21.22282936.
68	

69 Manuscript word count: 3372

It is made available under a CC-BY 4.0 International license .

#### 70 Clinical validation of novel second-trimester preterm preeclampsia risk predictors combining clinical

- 71 variables and serum protein biomarkers
- 72

73 Précis

- 74 Combining novel serum protein biomarkers and selected clinical variables for preterm preeclampsia
- 75 prediction outperforms widely used clinical risk assessment algorithms currently recommended by
- 76 practice guidelines.
- 77

### 78 Abstract

- 79 Objective
- 80 To develop and validate mid-trimester preterm preeclampsia (PE) risk predictors combining clinical

factors and serum protein analytes, and to compare their performance with those of widely used clinical

82 and risk assessment algorithms endorsed by professional societies.

83

84 Methods

85 This was a secondary analysis of data from two large, multicenter studies in pregnant individuals (PAPR, NCT01371019; TREETOP, NCT02787213), originally conducted to discover, verify, and validate a serum 86 87 proteomic predictor of preterm birth risk. Serum protein abundances were determined by mass 88 spectrometry. Classifier models combined one or two novel protein ratio(s) with a composite clinical 89 variable, denoted as ClinRisk3, which included prior PE, pre-existing hypertension, or pregestational 90 diabetes. Predictive performance was assessed for the full validation cohort and for a subset that had 91 early gestational age (GA) dating via ultrasound. Classifier performance was compared directly to the 92 U.S. Preventive Services Task Force (USPSTF) algorithm for identification of pregnancies that should 93 receive low-dose aspirin (LDASA) for PE prevention.

It is made available under a CC-BY 4.0 International license .

94	9	4
----	---	---

- 95 Results
- 96 Nine of nine prespecified classifier models were validated for risk of preterm PE with delivery <37
- 97 weeks' gestation. Areas under the receiver operating characteristic curve ranged from 0.72-0.78 in the
- 98 full validation cohort, compared to 0.68 for both ClinRisk3 alone and for the USPSTF algorithm. In the
- 99 early GA dating subcohort, an exemplar predictor, ClinRisk3 + inhibin subunit beta C chain/sex hormone
- 100 binding globulin (ClinRisk3+INHBC/SHBG) showed a markedly lower screen positive rate (11.1% vs
- 43.3%) and higher positive predictive value (13.0% vs 5.0%) and odds ratio (9.93 vs 5.24) than USPSTF.
- 102 Its performance was similar in nulliparas and all parities.
- 103
- 104 Conclusion
- 105 Nine preterm PE risk predictors were identified, validated in an independent cohort, and shown to be
- 106 more predictive than the USPSTF-endorsed algorithm. Our results indicate that a single blood test
- 107 performed in the first half of pregnancy can be used for personalized PE risk assessment, particularly for
- 108 pregnancies with minimal or no identified clinical risk factors, including nulliparas. Results can be used to
- 109 guide personalized pregnancy management, including but not restricted to LDASA for PE prophylaxis,
- and serve as a basis for developing new prevention strategies.
- 111
- 112 Funding Source
- 113 Sera Prognostics, Inc.

It is made available under a CC-BY 4.0 International license .

# 114 Introduction

115	Preeclampsia (PE) occurs in $\sim$ 5-7% of pregnancies <sup>1</sup> and is implicated in 14% of maternal <sup>2</sup> and 10-25% of
116	perinatal <sup>3</sup> deaths. It is associated with approximately one-quarter of all preterm births (PTBs) and 50%
117	of medically indicated PTBs. <sup>4</sup> The only cure for PE is delivery, with other therapies focused on preventing
118	or delaying onset (low-dose aspirin [LDASA]), <sup>5</sup> preventing end-organ damage (antihypertensive
119	medications to prevent strokes <sup>6</sup> and magnesium sulfate to prevent seizures), <sup>7</sup> and reducing neonatal
120	complications of prematurity (antenatal steroids). <sup>7</sup> Because PE-associated perinatal morbidity and
121	mortality and healthcare costs correlate with prematurity, <sup>8,9</sup> accurate prediction of preterm PE
122	(gestational age [GA] at delivery [GAD] <37 weeks) is of greater clinical and economic value than
123	prediction of term PE.
124	Until recently, PE prediction relied largely on clinical risk factors, including: PE in a previous
125	pregnancy; high body mass index (BMI); maternal chronic hypertension, diabetes, renal disease, and
126	autoimmune conditions; and obstetric characteristics such as multiple gestation and use of assisted
127	reproductive technologies. <sup>7</sup> PE and gestational hypertension in a previous pregnancy are among the
128	most predictive and commonly used risk factors but are irrelevant in nulliparous pregnancies.
129	Numerous PE-associated molecular biomarkers have been reported, <sup>10-13</sup> including soluble fms-
130	like tyrosine kinase 1 (sFlt-1) and placental growth factor (PIGF). In patients with clinically suspected PE,
131	sFlt-1 and PIGF measurement enables earlier diagnosis and/or modestly decreases adverse maternal
132	outcomes. <sup>14,15</sup> but do not adequately predict PE risk in asymptomatic pregnancies. Strategies
133	incorporating combinations of serum analytes, patient history, blood pressure, and uterine artery
134	pulsatility index accurately predict PE risk in asymptomatic pregnancies but are not widely used, as they
135	require sophisticated equipment with trained sonographers along with molecular analyses. <sup>16,17</sup> Also,
136	sFlt-1 and PIGF clinical studies have focused on late-onset PE; included only cases conforming to classical
137	definitions; or grouped PE cases across all GAs and/or severities together. Since PE is highly

It is made available under a CC-BY 4.0 International license .

heterogeneous,<sup>18,19</sup> biomarker studies should at minimum assess performance for early-onset and late onset cases separately.<sup>8,20,21</sup>

140 There is an urgent need for an accurate, safe, and practical predictor for preterm PE, particularly 141 for nulliparas. A predictor with good AUC (>0.70), sensitivity (>50%), and PPV (>5%) at a reasonably low 142 screen positive rate (SPR) (<15%) would markedly improve identification of high-risk pregnancies for 143 LDASA prophylaxis, increased surveillance, and research studies compared to current clinical paradigms, while a high negative predictive value (NPV; >99%) would enable low-risk patients to safely forgo or 144 145 discontinue unnecessary interventions. This study aimed to develop and validate a mid-trimester predictor comprising molecular biomarkers and relevant clinical factors across demographically. 146 147 geographically, and temporally diverse populations, comparing predictive performance to that of currently used risk assessment paradigms. 148 149 150 Methods 151 Biomarker development was based on U.S. National Academy of Medicine guidelines.<sup>22</sup> This was a

secondary analysis, using data from two large, multicenter U.S. cohort studies, conducted to discover,

153 verify, and validate risk predictors for preterm PE. The Proteomic Assessment of Preterm Risk (PAPR,

154 NCT01371019)<sup>23</sup> and the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor

155 (TREETOP, NCT02787213)<sup>24</sup> studies were prospective, observational studies conducted to develop a

156 maternal serum-based proteomic biomarker for PTB risk stratification. Study approvals were provided

157 by site IRBs, and participants provided written informed consent.

PAPR and TREETOP enrolled gravidas ≥18 years of age with singleton pregnancies from 17<sup>0/7</sup> 28<sup>6/7</sup> or 17<sup>0/7</sup>-21<sup>6/7</sup> weeks' gestation, respectively, and excluded pregnancies with planned delivery <37<sup>0/7</sup>
 weeks' gestation, major anomalies or chromosomal disorders, or planned cervical cerclage. GA was

161 determined according to ACOG criteria<sup>25,26</sup>. In TREETOP, progesterone use after 13<sup>6/7</sup> weeks' gestation

It is made available under a CC-BY 4.0 International license .

was an exclusion criterion. Demographic, medical and pregnancy history, medication, and post-delivery
 maternal and infant outcome information was collected. No attempt was made to control for LDASA use
 in these studies. Adjudication of PE and PTB cases was blinded, occurring prior to database lockdown
 and analyses.

166 Discovery was performed in a PAPR-derived cohort that was distinct from the TREETOP-derived 167 verification and validation cohorts (Fig. 1). The discovery and verification/validation cohorts included blood samples drawn 18<sup>0/7</sup>-22<sup>6/7</sup> and 18<sup>0/7</sup>-20<sup>6/7</sup> weeks' gestation, respectively. The discovery cohort 168 169 used a broader GA at blood draw (GABD) window to increase sample size. TREETOP subjects enrolled before April 18, 2018 were randomly assigned by an independent third-party statistician to blinded 170 verification (one-third) or validation (two-thirds) cohorts.<sup>24</sup> The validation cohort also included six 171 172 months of later enrollment at four additional sites not represented in the verification cohort. Cases were 173 defined as subjects with PE who delivered <37 weeks' gestation, and controls were defined as noncases, 174 inclusive of term PE and sPTB.

Maternal blood was collected, processed and stored as described previously.<sup>23,24</sup> Serum samples
 were depleted of abundant proteins, reduced, alkylated, and digested with trypsin. Stable isotope

177 standard (SIS) peptides were added post-digest, and peptides were analyzed by a liquid

178 chromatography-multiple reaction monitoring mass spectrometry assay.<sup>23,27</sup> Quantification was based

179 on peptide response ratios, wherein the area of each endogenous peptide was divided by that of its

180 corresponding SIS. Sample batches were required to meet quality control metrics.

Biomarker measurements were made for 77 proteins, comprising those enriched for pathways relevant to pregnancy conditions and quality control proteins. Proteins for building classifier models were prefiltered using analytical performance criteria, including mass spectrometry peak area cutoffs, coefficients of variance from replicate quality control samples, and preanalytic stability. Simple models were then constructed to avoid overfitting and to leverage protein ratios for normalizing and amplifying

It is made available under a CC-BY 4.0 International license .

- 186 predictive signals<sup>23</sup>. Models included one novel two-protein ratio and a composite clinical variable.
- 187 Based on strong predictive performance in nulliparous individuals, the log ratio of insulin-like growth
- 188 factor-binding protein 4 (IBP4) to sex hormone-binding globulin (SHBG) was included in models as a
- 189 second two-protein ratio unless SHBG was part of the novel ratio. Among many clinical factors specified
- in current practice guidelines,<sup>7,28-32</sup> three (PE in a previous pregnancy, pre-existing hypertension, and
- 191 pregestational diabetes) were selected and combined into one variable (ClinRisk3), which was deemed
- 192 positive if any was true for the subject. This simple, fixed approach reduced overfitting, leveraged prior
- 193 biomarker knowledge, and produced classifiers that followed two model structures:
- 194
- 1.  $A_1$ \*log(IBP4/SHBG) +  $A_2$ \*ClinRisk3 + A3\*log(X/Y) or
- 195

2.  $A_1$ \*ClinRisk3 +  $A_2$ \*log (X/SHBG)

where X and Y are protein analytes, identified herein by Uniprot name without species identifier. Model
 coefficients A<sub>i</sub> were fit using logistic regression.

In discovery, models were ranked by a combination of area under the receiver operating characteristic curve (AUC) and correlation with GAD amongst preeclamptic subjects. Candidate models ascertained in discovery were confirmed and tuned in verification to account for temporal changes in care and population, then validated by an independent third-party statistician. Each classifier was initially validated using AUC, then *P*-value, for three score thresholds distinguishing higher from lower risk. Thresholds were predefined based on discovery performance to allow for sensitivity and specificity tradeoffs and to enable use in varied clinical settings.

Previously we showed that for prediction of spontaneous PTB using protein biomarkers, better estimation of test performance is obtained in more precisely GA-dated individuals.<sup>33</sup> Since crown-rump length is more precise when determined prior to 9<sup>0/7</sup> weeks' gestation,<sup>26</sup> post-validation performance metrics were calculated on a sub-cohort comprised of subjects dated by ultrasound prior to 9<sup>0/7</sup>-weeks' gestation (early GA dating). Performance metrics were calculated for GA cutoffs of <37 and <34 weeks in

It is made available under a CC-BY 4.0 International license .

210 all subjects and in nulliparous individuals. PE prevalence was calculated on the TREETOP validation 211 cohort and was consistent with the broader U.S. population, as represented by National Vital Statistics 212 System (NVSS) reporting<sup>34</sup> and Lisonkova et al. (2013)<sup>8</sup> (e.g., for PE <34 weeks: TREETOP, 1.13%; 213 Lisonkova, 1.24%; P=0.78). 214 Guidelines<sup>35</sup> set by the U.S. Preventive Services Task Force (USPSTF) for PE clinical risk factor 215 assessment were compared to the biomarker-driven model. The TREETOP validation dataset contained 216 most USPSTF-prescribed clinical risk factors, including prior history of preeclampsia, chronic 217 hypertension, type 1 or type 2 diabetes, kidney disease, multi-gestational birth, elevated pre-pregnancy body mass index, instances of nulliparous births, and maternal African American heritage (attributed to 218 219 socioeconomic factors). Using these variables, a classifier was developed to approximate the USPSTF risk 220 assessment and compare its performance with biomarker-driven models using the same predefined 221 benchmarks. 222 Analyses were conducted according to prespecified protocols. Laboratory personnel and 223 statisticians were blinded to clinical data. Data linked to classifier scores were analyzed by an independent third-party statistician. Type I error was controlled by fixed sequence hypothesis 224 225 testing.<sup>36,37</sup> The sample size of the validation sub-cohort was shown to have 84% power at 5% alpha to 226 detect by Fisher's exact test an enrichment of spontaneous PTB cases above a predictor score threshold associated with two-fold increased risk.<sup>38</sup> For the purpose of validating preterm PE classifiers, this sub-227 228 cohort was estimated to show >90% power at 5% alpha to detect by regression test a significant

enrichment above a 75% sensitivity threshold. At such a threshold, the sub-cohort sample size was

estimated to produce a 95% CI width for sensitivity of <25% and for specificity of <5%.

Unless otherwise specified, all statistical tests were 2-tailed at significance <0.05 and performed in R v3.5.1 or higher.<sup>39</sup> Count differences in categorical variables were assessed using the chi-squared test, and median differences in continuous variables were assessed with the Wilcoxon test.<sup>40</sup>

It is made available under a CC-BY 4.0 International license .

234	Comparison across cohorts was performed using the Kruskal-Wallis test. Overall predictive performance
235	was assessed via AUC with direction of effect prespecified, significance assessed with a 1-sided Wilcoxon
236	test, and confidence intervals (CI) calculated using DeLong's method. <sup>41</sup> Clinical validity was assessed
237	using predictive performance and statistically significant stratification of preterm PE subjects above vs
238	below threshold scores. Following validation, sensitivity, specificity, PPV, NPV, SPR, likelihood ratios
239	(LR+/-), and odds ratios (OR) were calculated for preterm PE (GAD <37 weeks), and early preterm PE
240	(GAD <34 weeks) for the entire validation cohort (all parities) and for nulliparas only. Calculation of
241	prevalence-dependent predictor performance used the prevalence of the analysed outcome in the
242	entire TREETOP-based validation cohort, as well as the early GA dating subset.
243	
244	Results
245	Characteristics of the discovery, verification, and validation cohorts are summarized in Table 1 and Fig.
246	<b>1</b> . Subjects delivering with preterm PE were more likely than controls to have higher BMI, prior PE,
247	chronic hypertension, pregestational diabetes, and longer neonatal hospital stays. GABD showed no
248	significant difference between cases and controls in any cohort.
249	No significant differences were seen across cohorts for chronic hypertension and pregestational
250	diabetes, but prior PE was increased among validation cohort controls (Appendix 1). There were also
251	significant differences between cohorts in race, ethnicity, parity, educational attainment, maternal age,
252	BMI, and GAD. Despite both case/control and cohort differences, regression analysis showed that
253	maternal age and BMI did not contribute independently to preterm PE risk. The significant difference in
254	GABD reflected the broader collection window in the discovery cohort.
255	Nine of nine classifiers ascertained in discovery showed acceptable predictive performance in
256	verification for risk of preterm PE with GAD <37 weeks. In validation, all nine exhibited significant AUCs
257	(0.72-0.78) for preterm PE risk prediction, significant risk stratification at three threshold scores, and

It is made available under a CC-BY 4.0 International license .

258	significant Pearson correlations between predictor score and GAD among individuals with PE (Appendix
259	2). ClinRisk3 alone exhibited an AUC of 0.68 for preterm PE, falling below the lower 95% CI of most of
260	the validated combined classifiers. Fig. 2 shows ROC curves for the predictor with the largest AUC (0.78),
261	ClinRisk3 + inhibin beta c chain/SHBG (ClinRisk3+INHBC/SHBG), in the full validation cohort for (A) all
262	parity and (B) nulliparas.
263	For prediction of preterm PE <37 weeks' gestation in gravidas with any parity or nulliparas,
264	Table 2 details ClinRisk3+INHBC/SHBG performance for validation cohort subjects with early GA dating,
265	and Appendix 3 shows its performance in the full validation cohort. In the early GA dating sub-cohort,
266	setting the ClinRisk3+INHBC/SHBG cutoff to achieve a specificity of at least 90%, the sensitivity for
267	prediction of preterm PE with GAD <37 weeks for all parities was 51.7%, with a SPR 11.1%, PPV 13.0%,
268	NPV 98.5%, and OR 9.93; the performance for nulliparas was extremely similar, with the exception of a
269	lower PPV (6.9%) and higher NPV (99.8%). We also applied USPSTF clinical practice guidelines <sup>35</sup> to our
270	validation cohort – either the entire validation cohort ( <b>Appendix 3</b> ) or the sub-cohort with early GA
271	dating (Table 2). In these comparisons, predictive performance for the combination of ClinRisk3 and
272	INHBC/SHBG was superior to that of USPSTF guidelines.
273	
274	Discussion
275	Nine classifier models predictive of preterm PE risk were validated, with ClinRisk3+INHBC/SHBG showing
276	the best overall performance. Requiring simplicity (one or two bivariate protein biomarkers and a
277	composite clinical variable) and using large, diverse, and temporally divergent cohorts mitigated
278	overfitting and enabled validation in an independent population. Three clinical features that differed
279	significantly between cases and controls in the discovery cohort (prior PE, pre-existing hypertension, and
280	pregestational diabetes) comprised the composite clinical variable. A fourth, BMI, was excluded as it did
281	not contribute independently to preterm PE risk, perhaps due to strong associations between BMI and

It is made available under a CC-BY 4.0 International license .

282	both diabetes and SHBG. <sup>42,43</sup> Emphasizing strong predictive performance in both nulliparous and
283	multiparous pregnancies during discovery ensures broad applicability. In the two source cohorts, Black
284	(17.8-19.0%) and Hispanic (37.3-41.2%) subjects were represented at proportions higher than those in
285	the general U.S. birthing population (14.1-15.2% Black; 23.7-24.2% Hispanic), <sup>44,45</sup> ensuring
286	generalizability.
287	Inhibin and activin, members of the transforming growth factor beta (TGF $eta$ ) family, are
288	dysregulated in pregnancy disorders. Elevated maternal serum Inhibin A was first reported as a
289	biomarker of fetal aneuploidy <sup>46</sup> but is also associated with PE, <sup>47,48</sup> including preclinical PE. <sup>49</sup> However,
290	Inhibin A, alone or in combination with other aneuploidy and fetal anomaly biomarkers, demonstrates
291	insufficient predictive performance for clinical use. <sup>50,51</sup> INHBC, a less well-characterized inhibin family
292	member comprised of activin C homodimers, was recently reported to function through activin
293	receptor-like kinase 7 (ALK7), which participates in angiogenesis, cytokine activity, hormone signaling,
294	and embryonic development. <sup>52</sup> Expressed in villous and extravillous trophoblasts, ALK7 is dysregulated
295	in placentas from individuals with PE <sup>53</sup> and is a mediator of hypoxia-induced impairment trophoblast
296	invasion. <sup>54</sup> A potential role for INHBC in extravillous trophoblast development and function may help
297	explain its predictive value for preterm PE (Fig. 3).
298	SHBG regulates biologically active free steroid hormone levels, <sup>55</sup> increases up to 10-fold in the
299	maternal circulation during pregnancy, and is expressed by placental trophoblasts. <sup>55,56</sup> SHBG
300	transcription is suppressed by pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-
301	$\alpha$ ), <sup>57</sup> which is relevant because inflammation, along with increased placental <sup>58</sup> and circulating <sup>59</sup> TNF- $\alpha$ , is
302	associated with PE (Fig. 3). Dysregulation of maternal circulating SHBG in PE has been reported by
303	some <sup>60</sup> and disputed by others <sup>61-65</sup> , perhaps due to variability in PE phenotype and GABD among studies.
304	Even in studies associating SHBG with PE, its predictive performance is poor. <sup>60</sup> In non-pregnant adults,
305	low serum SHBG has been associated with insulin resistance, <sup>66</sup> Type 2 diabetes, <sup>67</sup> and endothelial

It is made available under a CC-BY 4.0 International license .

306	dysfunction. <sup>68</sup> In one study, gravidas with low first-trimester SHBG and PIGF were at highest risk of
307	developing PE, leading authors to conclude that dysregulated angiogenesis and insulin resistance
308	exerted additive effects on PE risk. <sup>66</sup> Similarly, these results suggest that SHBG is an independent PE risk
309	predictor due to potential effects on insulin resistance and endothelial function, and predictive
310	performance improves markedly when combined with an angiogenic factor such as INHBC.
311	Since the validated ClinRisk3+INHBC/SHBG predictor makes early risk assessment possible for
312	preterm PE (<37 weeks) in a given pregnancy for any parity, it can enable individualized clinical
313	management. Individuals at higher risk can be assigned to increased surveillance (e.g., more frequent
314	antenatal visits, home blood pressure monitoring) for early detection of PE and associated
315	complications, along with nutritional modification, exercise coaching, and other interventions, <sup>69</sup> while
316	those at lower risk can safely avoid unnecessary interventions. Determining whether our predictors will
317	be useful for decision-making regarding LDASA prophylaxis requires more study, to establish LDASA
318	efficacy among patients for whom guideline criteria and the predictors produce discordant risk
319	assessments.
320	ClinRisk3+INHBC/SHBG provided excellent stratification of subjects at elevated risk for early-
321	onset preterm PE (diagnosis <34 weeks' GA), an outcome with a large clinical burden and unmet need.
322	ACOG recommends delivery for PE diagnosed ≥34 weeks' GA and expectant management with close
323	observation for those diagnosed earlier. <sup>7</sup> Clark et al. (2023) <sup>70</sup> recently recommended changes to
324	classification of different PE subtypes to better reflect the type and degree of associated organ
325	dysfunction. We acknowledge that, if adopted, such recommendations may alter clinical decision-
326	making relevant to timing of delivery for PE. In addition, new prevention or treatment strategies may be
327	developed. Any of these developments may require us to reassess predictor performance in the
328	appropriate contexts.

It is made available under a CC-BY 4.0 International license .

329	Clinical practice guidelines include expectations for test performance, including high PPV, to
330	limit overtreatment. <sup>7</sup> However, PPV is impacted by a condition's prevalence. This study validated
331	predictive algorithms for preterm PE, a clinically important yet low-prevalence PE phenotype, in a cohort
332	with a PE rate similar to the overall U.S. prevalence (2.7% preterm PE, 7.7% all PE). This contrasts with a
333	recent RNA biomarker study <sup>71</sup> that interrogated PE at any GA in a high-risk population (PE rate of
334	13.6%), which reported a sensitivity of 75.0% and a PPV of 32.3%. We chose to establish a threshold at
335	approximately a 10% false positive rate (FPR), as this is a common practice that helps to avoid
336	overtreatment. It is also common to establish a threshold that results in 10% of a population being
337	screen positive. As our 10% thresholds result in approximately an 11-12% SPR, the performance
338	estimates provided here apply generally for both approaches.
339	Importantly, according to the current standard of care, PE risk is assessed using a range of
340	clinical algorithms. Specifically, in a large Danish mixed parity cohort, National Institute of Health and
341	Care Excellence (NICE) guidelines <sup>28</sup> had a sensitivity of 47%, PPV of 5.4%, and NPV of 99.6% at a SPR of
342	8.1%, while American College of Obstetrics and Gynecology (ACOG) guidelines <sup>7</sup> had a sensitivity of
343	60.5%, PPV of 5.6%, and NPV of 99.7% at a SPR of 18.2% for preterm preeclampsia <37 weeks' GA. $^{72}$ In
344	our validation cohort, we applied USPSTF clinical practice guidelines, which yielded a sensitivity of
345	79.3%, PPV of 5.0%, and NPV of 99.0% at a SPR of 43.4% for preterm preeclampsia <37 weeks' GA. The
346	Fetal Medicine Foundation's (FMF) recommended a more involved screening algorithm <sup>73</sup> , including
347	maternal risk factors, maternal mean arterial pressure, the uterine artery pulsatility index, and serum
348	PLGF, which has a reported 79.9% sensitivity, 4.4% PPV, and 99.8% NPV at a SPR of 14.7% for all parities,
349	and 79.0% sensitivity, 3.8% PPV, and 99.8% NPV at a SPR of 19.2% for nulliparas, for preterm PE. <sup>74</sup>
350	Consisting of straightforward measurement of 2 proteins in a single blood sample combined
351	with easily ascertained clinical factors, the performance of ClinRisk3+INHBC/SHBG in the total validation
352	cohort (sensitivity 51.7%, PPV of 13.0%, and NPV of 98.5% at a SPR of 11.1%) and specifically in

It is made available under a CC-BY 4.0 International license .

353 nulliparas (sensitivity 53.3%, PPV of 6.9%, and NPV of 99.8% at a SPR of 11.7%) is superior to standard-354 of-care clinical risk assessment approaches endorsed by NICE. ACOG, and USPSTF, and also compares 355 favorably with the more burdensome approach endorsed by the FMF, which is comprised of not only 356 clinical factors and a protein biomarker, but also uterine artery Doppler measurement, which is 357 unfeasible for universal screening. ClinRisk3+INHBC/SHBG and the other predictors validated in this 358 study can be used to select high-risk pregnancies for interventional studies of prophylactic or 359 therapeutic agents. Determining whether preventive or therapeutic interventions alter biomarker levels 360 in maternal serum is also of interest. Clinical application of a screening test is a two-step process: The 361 first step, reported here, is validation of the biomarkers' predictive abilities. The second, demonstrating 362 clinical utility – i.e., improved outcomes, cost effectiveness, and ease of implementation – requires 363 additional work. 364 Strengths of the study include the large, diverse, and temporally distinct datasets used for 365 discovery, verification, and validation. The composite clinical variable uses readily ascertained factors,

and the biomarkers were prefiltered for excellent performance in ambient temperature sample

367 transport conditions. These properties support practicality for clinical use. Limitations include the

368 modest number of early preterm PE cases due to the low prevalence of the condition and a mid-

trimester blood draw window (18<sup>0/7</sup>-22<sup>6/7</sup> weeks' GA) that falls within the guideline-recommended

370 timeframe for LDASA initiation (12-28 week's GA, optimally <16 weeks' GA).<sup>7</sup>

In summary, nine mid-trimester preterm PE risk predictors, designed to assess both proteomic biomarkers and clinical risk factors from 18-20 weeks' gestation, demonstrated predictive ability superior to that of clinical factors alone. ClinRisk3+INHBC/SHBG includes biomarkers with functional relevance to pregnancy. All show promise for detecting risk of PE <34 weeks' GA and identifying presymptomatic individuals who can benefit from increased surveillance, LDASA prophylaxis, and future therapies.

It is made available under a CC-BY 4.0 International license .

#### 377 References

- 378 1. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and
- 379 Perspectives. Circ Res. Mar 29 2019;124(7):1094-1112. doi:10.1161/CIRCRESAHA.118.313276
- 380 2. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal
- death: a WHO systematic analysis. Lancet Glob Health. Jun 2014;2(6):e323-33. doi:10.1016/S2214-
- 382 109X(14)70227-X
- 383 3. Vogel JP, Souza JP, Mori R, Morisaki N, Lumbiganon P, Laopaiboon M, et al. Maternal
- 384 complications and perinatal mortality: findings of the World Health Organization Multicountry Survey on
- 385 Maternal and Newborn Health. *BJOG*. Mar 2014;121 Suppl 1:76-88. doi:10.1111/1471-0528.12633
- 4. Ananth CV, Vintzileos AM. Medically indicated preterm birth: recognizing the importance of the
- 387 problem. Clin Perinatol. Mar 2008;35(1):53-67, viii. doi:10.1016/j.clp.2007.11.001
- 388 5. Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N. Aspirin Use to Prevent
- 389 Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for
- the US Preventive Services Task Force. JAMA. Sep 28 2021;326(12):1192-1206.
- 391 doi:10.1001/jama.2021.8551
- 392 6. Chronic Hypertension in Pregnancy. ACOG Practice Bulletin No. 203. American College of
- 393 Obstetricians and Gynecologists. Obstet Gynecol. Jan 2019;133(1)e26-
- 394 e50.doi:10.1097/AOG.000000000003020
- 395 7. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. American
- 396 College of Obstetricians and Gynecologists. Obstet Gynecol. Jun 2020;135(6)e237-
- 397 e260.doi:10.1097/AOG.00000000003891
- 398 8. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with
- early-versus late-onset disease. *Am J Obstet Gynecol*. Dec 2013;209(6):544 e1-544 e12.
- 400 doi:10.1016/j.ajog.2013.08.019

It is made available under a CC-BY 4.0 International license .

- 401 9. Hao J, Hassen D, Hao Q, Graham J, Paglia MJ, Brown J, et al. Maternal and Infant Health Care
- 402 Costs Related to Preeclampsia. *Obstet Gynecol*. Dec 2019;134(6):1227-1233.
- 403 doi:10.1097/AOG.00000000003581
- 404 10. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. *Mol*
- 405 *Aspects Med*. Apr 2007;28(2):227-44. doi:10.1016/j.mam.2007.04.002
- 406 11. Bahado-Singh RO, Syngelaki A, Akolekar R, Mandal R, Bjondahl TC, Han B, et al. Validation of
- 407 metabolomic models for prediction of early-onset preeclampsia. Am J Obstet Gynecol. Oct
- 408 2015;213(4):530 e1-530 e10. doi:10.1016/j.ajog.2015.06.044
- 409 12. Koster MP, Vreeken RJ, Harms AC, Dane AD, Kuc S, Schielen PC, et al. First-Trimester Serum
- 410 Acylcarnitine Levels to Predict Preeclampsia: A Metabolomics Approach. *Dis Markers*.
- 411 2015;2015:857108. doi:10.1155/2015/857108
- 412 13. Srinivasan S, Treacy R, Herrero T, Olsen R, Leonardo TR, Zhang X, et al. Discovery and
- 413 Verification of Extracellular miRNA Biomarkers for Non-invasive Prediction of Pre-eclampsia in
- 414 Asymptomatic Women. Cell Rep Med. May 19 2020;1(2)doi:10.1016/j.xcrm.2020.100013
- 415 14. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive Value of the
- 416 sFlt-1:PIGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med*. Jan 7 2016;374(1):13-22.
- 417 doi:10.1056/NEJMoa1414838
- 418 15. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing
- to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-
- 420 randomised controlled trial. Lancet. May 4 2019;393(10183):1807-1818. doi:10.1016/S0140-

421 6736(18)33212-4

- 422 16. Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi Brumatti L, et al. First
- 423 trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history

It is made available under a CC-BY 4.0 International license .

- 424 for the prediction of preeclampsia. *Placenta*. Jun 2012;33(6):495-501.
- 425 doi:10.1016/j.placenta.2012.03.003
- 426 17. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and
- 427 small for gestational age at 11-13 weeks. *Fetal Diagn Ther*. 2013;33(1):16-27. doi:10.1159/000341712
- 428 18. Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ. Unsupervised Placental
- 429 Gene Expression Profiling Identifies Clinically Relevant Subclasses of Human Preeclampsia. *Hypertension*.
- 430 Jul 2016;68(1):137-47. doi:10.1161/HYPERTENSIONAHA.116.07293
- 431 19. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L, Global Pregnancy C. Subtypes of
- 432 Preeclampsia: Recognition and Determining Clinical Usefulness. *Hypertension*. May 5 2021;77(5):1430-
- 433 1441. doi:10.1161/HYPERTENSIONAHA.120.14781
- 434 20. Robillard PY, Dekker G, Scioscia M, Saito S. Progress in the understanding of the pathophysiology
- 435 of immunologic maladaptation related to early-onset preeclampsia and metabolic syndrome related to
- 436 late-onset preeclampsia. Am J Obstet Gynecol. Feb 2022;226(2S):S867-S875.
- 437 doi:10.1016/j.ajog.2021.11.019
- 438 21. Masini G, Foo LF, Tay J, Wilkinson IB, Valensise H, Gyselaers W, Lees CC. Preeclampsia has two
- 439 phenotypes which require different treatment strategies. Am J Obstet Gynecol. Feb 2022;226(2S):S1006-
- 440 S1018. doi:10.1016/j.ajog.2020.10.052
- 441 22. Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical
- 442 Trials, Board on Health Care Services, Board on Health Sciences Policy, Institute of Medicine. In: Micheel
- 443 CM, Nass SJ, Omenn GS, eds. Evolution of Translational Omics: Lessons Learned and the Path Forward.
- 444 National Academies Press (US)
- 445 Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2012.

It is made available under a CC-BY 4.0 International license .

- 446 23. Saade GR, Boggess KA, Sullivan SA, Markenson GR, Iams JD, Coonrod DV, et al. Development and
- 447 validation of a spontaneous preterm delivery predictor in asymptomatic women. *Am J Obstet Gynecol*.
- 448 May 2016;214(5):633 e1-633 e24. doi:10.1016/j.ajog.2016.02.001
- 449 24. Markenson GR, Saade GR, Laurent LC, Heyborne KD, Coonrod DV, Schoen CN, et al. Performance
- 450 of a proteomic preterm delivery predictor in a large independent prospective cohort. Am J Obstet
- 451 *Gynecol MFM*. Aug 2020;2(3):100140. doi:10.1016/j.ajogmf.2020.100140
- 452 25. American College of Obstetricians and Gynecologists. Committee opinion no 611: method for
- 453 estimating due date. *Obstet Gynecol*. Oct 2014;124(4):863-866.
- 454 doi:10.1097/01.AOG.0000454932.15177.be
- 455 26. Methods for Estimating the Due Date. Committee Opinion No 700 American College of
- 456 Obstetricians and Gynecologists. Obstet Gynecol. May 2017;129(5)e150-
- 457 e154.doi:10.1097/AOG.000000000002046
- 458 27. Bradford C, Severinsen R, Pugmire T, Rasmussen M, Stoddard K, Uemura Y, et al. Analytical
- 459 validation of protein biomarkers for risk of spontaneous preterm birth. *Clinical Mass Spectrometry*.
- 460 2017/01/01/2017;3:25-38. doi:10.1016/j.clinms.2017.06.002
- 461 28. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis
- 462 and management (NICE Guideline, NG 133). Accessed November 22, 2022,
- 463 <u>https://www.ncbi.nlm.nih.gov/books/NBK546004/</u>
- 464 29. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton M, North RA, et al. SOMANZ guidelines for the
- 465 management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. Oct
- 466 2015;55(5):e1-29. doi:10.1111/ajo.12399
- 467 30. Magee LA, Smith GN, Bloch C, Cote AM, Jain V, Nerenberg K, et al. Guideline No. 426:
- 468 Hypertensive Disorders of Pregnancy: Diagnosis, Prediction, Prevention, and Management. J Obstet
- 469 *Gynaecol Can*. May 2022;44(5):547-571 e1. doi:10.1016/j.jogc.2022.03.002

It is made available under a CC-BY 4.0 International license .

- 470 31. World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-
- 471 *Eclampsia and Eclampsia.* Geneva: World Health Organization; 2011.
- 472 32. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive
- 473 Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for
- 474 International Practice. *Hypertension*. Jul 2018;72(1):24-43. doi:10.1161/HYPERTENSIONAHA.117.10803
- 475 33. Burchard J, Saade GR, Boggess KA, Markenson GR, Iams JD, Coonrod DV, et al. Better Estimation
- 476 of Spontaneous Preterm Birth Prediction Performance through Improved Gestational Age Dating. J Clin
- 477 *Med*. May 19 2022;11(10)doi:10.3390/jcm11102885
- 478 34. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2021.
- 479 *Natl Vital Stat Rep.* Jan 2023;72(1):1-53.
- 480 35. Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, et al. Screening
- 481 for Preeclampsia: US Preventive Services Task Force Recommendation Statement. Jama. Apr 25
- 482 2017;317(16):1661-1667. doi:10.1001/jama.2017.3439
- 36. Dmitrienko A, Tamhane A, Bretz F, eds. *Multiple Testing Problems in Pharmaceutical Statistics*.
  CRC Press; 2009.
- 485 37. Dmitrienko A, D'Agostino RB, Sr., Huque MF. Key multiplicity issues in clinical drug development.
- 486 Stat Med. Mar 30 2013;32(7):1079-111. doi:10.1002/sim.5642
- 487 38. Burchard J, Polpitiya AD, Fox AC, Randolph TL, Fleischer TC, Dufford MT, et al. Clinical Validation
- 488 of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated
- 489 Clinical Outcomes: A Replication Study. J Clin Med. Oct 29 2021;10(21):5088. doi:10.3390/jcm10215088
- 490 39. R Foundation. The R Project for Statistical Computing. Accessed August 1, 2022, https://www.r-

491 project.org/

It is made available under a CC-BY 4.0 International license .

- 492 40. Yoshida K, Bartel A. tableone: Create 'Table 1' to Describe Baseline Characteristics with or
- 493 without Propensity Score Weights; R package version 0.13.2. Accessed November 21, 2022,
- 494 <u>https://cran.r-project.org/web/packages/tableone/index.html</u>
- 495 41. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated
- 496 receiver operating characteristic curves: a nonparametric approach. *Biometrics*. Sep 1988;44(3):837-45.
- 497 42. Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM. The association of obesity with sex
- 498 hormone-binding globulin is stronger than the association with ageing--implications for the
- interpretation of total testosterone measurements. *Clin Endocrinol (Oxf)*. Dec 2015;83(6):828-33.
- 500 doi:10.1111/cen.12768
- 43. Birkebaek NH, Lange A, Holland-Fischer P, Kristensen K, Rittig S, Vilstrup H, et al. Effect of weight
- reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in
- 503 obese children. Eur J Endocrinol. Dec 2010;163(6):895-900. doi:10.1530/EJE-10-0538
- 44. Osterman MJK, Hamilton BE, Martin, J.A., Driscoll AKV, C.P. Births: Final Data for 2020. Division
- of Vital Statistics, National Center for Health Statistics, U.S. Centers for Disease Control and Prevention.
- 506 Updated 2022 Feb 7. Accessed February 9, 2022, https://www.cdc.gov/nchs/nvss/births.htm
- 507 45. March of Dimes Peristats. Births. Accessed July 1, 2023,
- 508 <u>https://www.marchofdimes.org/peristats/data?reg=99&top=2&stop=10&lev=1&slev=1&obj=3</u>
- 509 46. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, et al. Dimeric
- 510 inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med. May 9 1996;334(19):1231-
- 511 6. doi:10.1056/NEJM199605093341904
- 512 47. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as
- 513 possible endocrine markers for pre-eclampsia. *Lancet*. May 3 1997;349(9061):1285-8.
- 514 doi:10.1016/s0140-6736(96)09264-1

It is made available under a CC-BY 4.0 International license .

515 48. Fraser RF, 2nd, McAsey ME, Coney P. Inhibin-A and pro-alpha C are elevated in preeclamptic

516 pregnancy and correlate with human chorionic gonadotropin. Am J Reprod Immunol. Jul 1998;40(1):37-

517 42. doi:10.1111/j.1600-0897.1998.tb00386.x

518 49. Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, et al. Serum inhibin A

and activin A are elevated prior to the onset of pre-eclampsia. *Hum Reprod*. Jul 2000;15(7):1640-5.

520 doi:10.1093/humrep/15.7.1640

521 50. Morris RK, Cnossen JS, Langejans M, Robson SC, Kleijnen J, Ter Riet G, et al. Serum screening

522 with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic

review and meta-analysis. *BMC Pregnancy Childbirth*. Aug 4 2008;8:33. doi:10.1186/1471-2393-8-33

524 51. Huang T, Bedford HM, Rashid S, Rasasakaram E, Priston M, Mak-Tam E, et al. Modified multiple

525 marker aneuploidy screening as a primary screening test for preeclampsia. *BMC Pregnancy Childbirth*.

526 Mar 8 2022;22(1):190. doi:10.1186/s12884-022-04514-4

527 52. Goebel EJ, Ongaro L, Kappes EC, Vestal K, Belcheva E, Castonguay R, et al. The orphan ligand,

528 activin C, signals through activin receptor-like kinase 7. *Elife*. Jun 23 2022;11doi:10.7554/eLife.78197

529 53. Nadeem L, Munir S, Fu G, Dunk C, Baczyk D, Caniggia I, et al. Nodal signals through activin

receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of

531 preeclampsia. Am J Pathol. Mar 2011;178(3):1177-89. doi:10.1016/j.ajpath.2010.11.066

532 54. Hu M, Wang Y, Meng Y, Hu J, Qiao J, Zhen J, et al. Hypoxia induced-disruption of lncRNA

533 TUG1/PRC2 interaction impairs human trophoblast invasion through epigenetically activating

534 Nodal/ALK7 signalling. J Cell Mol Med. Jul 2022;26(14):4087-4100. doi:10.1111/jcmm.17450

535 55. Hammond GL. Diverse roles for sex hormone-binding globulin in reproduction. *Biol Reprod*. Sep

536 2011;85(3):431-41. doi:10.1095/biolreprod.111.092593

It is made available under a CC-BY 4.0 International license .

537 56. Larrea F, Diaz L, Carino C, Larriva-Sahd J, Carrillo L, Orozco H, Ulloa-Aguirre A. Evidence that

538 human placenta is a site of sex hormone-binding globulin gene expression. *J Steroid Biochem Mol Biol*.

539 Oct 1993;46(4):497-505. doi:10.1016/0960-0760(93)90104-5

540 57. Simo R, Saez-Lopez C, Barbosa-Desongles A, Hernandez C, Selva DM. Novel insights in SHBG

regulation and clinical implications. *Trends Endocrinol Metab*. Jul 2015;26(7):376-83.

542 doi:10.1016/j.tem.2015.05.001

543 58. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, Barber WH, Hale EA, Martin JN, Jr., Bennett

544 WA. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin

545 10 is increased in preeclampsia. *Am J Obstet Gynecol*. Oct 1999;181(4):915-20. doi:10.1016/s0002-

546 9378(99)70325-x

547 59. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with

548 preeclampsia. Am J Reprod Immunol. Aug 1998;40(2):102-11. doi:10.1111/j.1600-0897.1998.tb00398.x

549 60. Yu CK, Papageorghiou AT, Bindra R, Spencer K, Nicolaides KH. Second-trimester sex hormone-

550 binding globulin and subsequent development of pre-eclampsia. J Matern Fetal Neonatal Med. Sep

551 2004;16(3):158-62. doi:10.1080/14767050400013297

552 61. Nevalainen J, Korpimaki T, Kouru H, Sairanen M, Ryynanen M. Performance of first trimester

553 biochemical markers and mean arterial pressure in prediction of early-onset pre-eclampsia. *Metabolism*.

554 Oct 2017;75:6-15. doi:10.1016/j.metabol.2017.07.004

555 62. Sharifzadeh F, Kashanian M, Fatemi F. A comparison of serum androgens in pre-eclamptic and

normotensive pregnant women during the third trimester of pregnancy. *Gynecol Endocrinol*. Oct

557 2012;28(10):834-6. doi:10.3109/09513590.2012.683061

558 63. Tuutti EK, Hamalainen EK, Sainio SM, Hiilesmaa VK, Turpeinen UL, Alfthan HV, Stenman UH.

559 Serum testosterone levels during early pregnancy in patients developing preeclampsia. Scand J Clin Lab

560 *Invest*. Sep 2011;71(5):413-8. doi:10.3109/00365513.2011.580858

It is made available under a CC-BY 4.0 International license .

- 561 64. Sun L, Jin Z, Teng W, Chi X, Zhang Y, Ai W, Wang P. Expression changes of sex hormone binding
- 562 globulin in GDM placental tissues. J Perinat Med. Nov 19 2011;40(2):129-35. doi:10.1515/JPM.2011.128
- 563 65. Anderson DC. Sex-hormone-binding globulin. *Clin Endocrinol (Oxf)*. Jan 1974;3(1):69-96.
- 564 doi:10.1111/j.1365-2265.1974.tb03298.x
- 565 66. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, et al. Insulin resistance
- 566 and alterations in angiogenesis: additive insults that may lead to preeclampsia. *Hypertension*. May
- 567 2004;43(5):988-92. doi:10.1161/01.HYP.0000124460.67539.1d
- 568 67. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin
- 569 resistance. Clin Endocrinol (Oxf). Mar 2013;78(3):321-9. doi:10.1111/cen.12086
- 570 68. Maggio M, Cattabiani C, Lauretani F, Mantovani M, Butto V, De Vita F, et al. SHBG and
- 571 endothelial function in older subjects. *Int J Cardiol*. Oct 3 2013;168(3):2825-30.
- 572 doi:10.1016/j.ijcard.2013.03.083
- 573 69. Roberts JM, King TL, Barton JR, Beck S, Bernstein IM, Buck TE, et al. Care plan for individuals at
- 574 risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-
- 575 up. Am J Obstet Gynecol. Sep 2023;229(3):193-213. doi:10.1016/j.ajog.2023.04.023
- 576 70. Clark SL, Saade GA, Tolcher MC, Belfort MA, Rouse DJ, Barton JR, et al. Gestational hypertension
- 577 and "severe" disease: time for a change. *Am J Obstet Gynecol*. May 2023;228(5):547-552.
- 578 doi:10.1016/j.ajog.2022.11.1280

579 71. Rasmussen M, Reddy M, Nolan R, Camunas-Soler J, Khodursky A, Scheller NM, et al. RNA profiles

- reveal signatures of future health and disease in pregnancy. *Nature*. Jan 2022;601(7893):422-427.
- 581 doi:10.1038/s41586-021-04249-w
- 582 72. Rode L, Ekelund CK, Riishede I, Rasmussen S, Lidegaard O, Tabor A. Prediction of preterm pre-
- eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to
- 584 2017. Ultrasound Obstet Gynecol. Oct 2021;58(4):561-567. doi:10.1002/uog.23693

It is made available under a CC-BY 4.0 International license .

- 585 73. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction.
- 586 *Am J Obstet Gynecol*. Feb 2022;226(2S):S1071-S1097 e2. doi:10.1016/j.ajog.2020.07.020
- 587 74. Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for pre-
- 588 eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation. *Ultrasound Obstet Gynecol*.
- 589 Aug 2018;52(2):186-195. doi:10.1002/uog.19112

Table 1. Demographic and clinical characteristics of preterm preeclampsia (PE) cases and noncases in the discovery, verification, and validation

cohorts.

		Dis	scovery (PAPR)		Verification (TREETOP) Validation (TREETOP			lation (TREETOP)			
		Preterm PE	No PE or		Preterm PE	Preterm PE No PE or			Preterm PE No PE or		
		<37 weeks'	PE ≥37 weeks'		<37 weeks'	PE ≥37 weeks'		<37 weeks'	PE ≥37 weeks'		
Cas	es and noncases	gestation	gestation	P value	gestation	gestation	P value	gestation	gestation	P value	
Nu	mber of subjects (n, %)	45 (3.3)	1307 (96.7)		34 (2.7)	1217 (97.3)		62 (2.7)	2227 (97.3)		
Ma	ternal age (y)			0.586			0.640			0.705	
	Median	26	27		28.5	30		30	29		
	IQR	24–31	23–32		27–32	25–33		25–34	25–33		
	Unknown (n)	0	0		0	0		0	0		
BM	1			0.003			0.027			<0.001	
	Median	29.6	26.6		28.3	26.1		30.9	25.8		
	IQR	26.17-38.0	22.7-32.4		25.7-32.9	22.6-31.0		25.9-35.5	22.3-31.1		
	Unknown (n)	1	23		1	14		1	25		
Ma	ternal race (n, %)			0.114			0.838			0.579	
	Black	13 (28.9)	224 (17.1)		5 (14.7)	233 (19.1)		14 (22.6)	393 (17.6)		
	White	29 (64.4)	952 (72.8)		21 (61.8)	757 (62.2)		34 (54.8)	1411 (63.4)		
	None of the above	3 (6.7)	131 (10.0)		7 (20.6)	205 (16.8)		12 (19.4)	370 (16.6)		
	Unknown (n)	0 (0.0)	0 (0.0)		1 (2.9)	22 (1.8)		2 (3.2)	53 (2.4)		
Maternal ethnicity (n, %)				0.180			0.104			0.243	
	Hispanic	12 (26.7)	492 (37.6)		20 (58.8)	495 (40.7)		30 (48.4)	895 (40.2)		
	Non-Hispanic	33 (73.3)	815 (62.4)		14 (41.2)	720 (59.2)		32 (51.6)	1332 (59.8)		
	Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	2 (0.2)		0 (0.0)	0 (0.0)		
Ma	ternal education level (n, %)			0.131			0.329			0.194	
	No high school graduation	17 (37.8)	338 (25.9)		4 (11.8)	192 (15.8)		10 (16.1)	317 (14.2)		
	High school degree/GED	21 (46.7)	635 (48.6)		21 (61.8)	558 (45.9)		35 (56.5)	1033 (46.4)		
	College degree	6 (13.3)	323 (24.7)		9 (26.5)	463 (38.0)		16 (25.8)	861 (38.7)		
	Unknown (n)	1 (2.2)	11 (0.8)		0 (0.0)	4 (0.3)		1 (1.6)	16 (0.7)		
Par	ity (n, %)			0.591			0.838			0.307	
	Nulliparous (P=0)	18 (40.0)	457 (35.0)		13 (38.2)	505 (41.5)		31 (50.0)	950 (42.7)		
	Multiparous (P≥1)	27 (60.0)	850 (65.0)		21 (61.8)	712 (58.5)		31 (50.0)	1277 (57.3)		
	Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		
Pre	vious PE (preterm + term) (n, %)			< 0.001			< 0.001			< 0.001	
	No	13 (48.1)	777 (91.4)		11 (52.4)	653 (91.7)		18 (58.1)	1102 (86.3)		
	Yes	14 (51.9)	73 (8.6)		10 (47.6)	59 (8.3)		13 (41.9)	175 (13.7)		
	Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		
Chr	onic hypertension (n, %)			<0.001			< 0.001			<0.001	
	No	35 (77.8)	1229 (94.0)		26 (76.5)	1154 (94.8)		37 (59.7)	2124 (95.4)		
	Yes	10 (22.2)	78 (6.0)		8 (23.5)	63 (5.2)		25 (40.3)	103 (4.6)		
	Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		
Pre	gestational diabetes mellitus (n, %)			< 0.001			0.001			< 0.001	

No	31 (68.9)	1250 (95.6)		28 (82.4)	1166 (95.8)		47 (75.8)	2118 (95.1)	
Yes	14 (31.1)	57 (4.4)		6 (17.6)	51 (4.2)		15 (24.2)	109 (4.9)	
Unknown (n)	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)	
Gestational age at blood draw (d)			0.233			0.854			0.600
Median	137	140		137	136		136.5	137	
IQR	133–143	132–148		134–140	132–141		130–141	133–141	
Unknown (n)	0	0		0	0		0	0	
Gestational age at delivery (d)			<0.001			<0.001			<0.001
Median	248	274		243.5	275		240	275	
IQR	236-254	267–279		224–253	269–281		226-252	270-280	
Unknown (n)	0	0		0	0		0	0	
Neonatal length of hospital stay (d)			<0.001			< 0.001			< 0.001
Median	5	3		13.5	2		11	2	
IQR	3-13	2-3		6-28	2-3		4-28	2-3	
Unknown (n)	0	12		0	6		2	7	
Neonatal gender (n, %)			0.920			0.809			0.676
Female	23 (51.1)	643 (49.2)		15 (44.1)	603 (49.5)		34 (54.8)	1100 (49.4)	
Male	22 (48.9)	664 (50.8)		19 (55.9)	613 (50.4)		28 (45.2)	1124 (50.5)	
Ambiguous	0 (0.0)	0 (0.0)		0 (0.0)	1 (0.1)		0 (0.0)	3 (0.1)	
Unknown	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)		0 (0.0)	3 (0.1)	

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparisons between cases (PE <37 weeks' gestation) and noncases (no PE or PE ≥37 weeks' gestation) were performed using Wilcoxon or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR<sup>23</sup> and TREETOP<sup>24</sup> study protocols. BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

It is made available under a CC-BY 4.0 International license .

# **Table 2.** Predictive performance of ClinRisk3+INHBC/SHBG and a U.S. Preventive Services Task Force

clinical risk factor-based classifier (representing standard care) for risk of preeclampsia with delivery <37

weeks' gestation in the early gestational age dating-restricted population.

Tested population	PE <37 weeks' GA cases/ total subjects (%)	Predictor	AUC (95% CI)	Sensitivity	Specificity	SPR	PPV	NPV	LR+	LR-	OR
Early GA dating	20/012 (2.2%)	ClinRisk3 + INHBC/SHBG	0.82 (0.75 – 0.89)	51.7%	90.3%	11.1%	13.0%	98.5%	5.31	0.53	9.93
All parity	29/912 (3.276)	USPSTF guidelines (standard of care)	0.69 (0.61 – 0.76)	79.3%	57.8%	43.4%	5.0%	99.0%	1.88	0.36	5.24
Early GA dating	15/276 (4.0%)	ClinRisk3 + INHBC/SHBG	0.81 (0.71 – 0.92)	53.3%	90.0%	11.7%	6.9%	99.8%	5.35	0.52	10.32
Nulliparas	15/376 (4.0%)	USPSTF guidelines (standard of care)	0.70 (0.61 – 0.80)	86.7%	54.3%	47.3%	2.6%	99.1%	1.90	0.25	7.72

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical risk variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; NPV, negative predictive value; LR+/-, positive and negative likelihood ratios; OR, odds ratio; PPV, positive predictive value; SHBG, sex hormone-binding globulin; SPR, screen positive rate; USPSTF, U.S. Preventive Services Task Force.

It is made available under a CC-BY 4.0 International license .

# **Figure Legends**

Fig. 1. Distribution of subjects in the discovery, verification, and validation cohorts.



GA, gestational age.

It is made available under a CC-BY 4.0 International license .

**Fig. 2**. Receiver operating characteristic performance for the preterm preeclampsia (PE) classifier ClinRisk3+INHBC/SHBG in the full validation cohort. The plots graph sensitivity (true positive rate) vs 1specificity (false positive rate) for preterm PE cases with gestational age at delivery <37 and <34 weeks among (A) all subjects and (B) nulliparous subjects only.



AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; INHBC, inhibin subunit beta c; SHBG, sex hormone binding globulin.

It is made available under a CC-BY 4.0 International license .

**Fig. 3.** Potential roles of INHBC and SHBG in placentation. (A) Activin C, a homodimer of INHBC, signals through the ALK7 receptor, which is itself dysregulated in preeclampsia. (B) SHBG expression has been demonstrated to be downregulated by pro-inflammatory cytokines in hepatocytes, and its extra-hepatic expression has been shown to include trophoblasts. (C) A model illustrating the association of INHBC, ALK7 and SHBG with abnormal placentation and aberrant spiral artery remodeling.



ActC, activin C, an INHBC homodimer; ACTRII, activin receptor type 2A; ALK7, activin A receptor type 1C; AMPK, AMP-activated protein kinase; c-Jun, Jun proto-oncogene, AP-1 transcription factor subunit; HNF-4α, hepatocyte nuclear factor 4 alpha; IkBα, NFkB inhibitor alpha; IL1β, interleukin 1 beta; IL1β, interleukin 1 beta receptor; INHBC, inhibin subunit beta c; JNK, mitogen-activated protein kinase 8; MEK1/2, mitogen-activated protein kinase kinases 1 and 2; MMP2/9, matrix metalloproteinases 2 and 9; NFkB, nuclear factor kappa B; SHBG, sex hormone binding globulin; SMAD2/3, SMAD family members 2 and 3; TIMP-1, TIMP metallopeptidase inhibitor 1; TNFα, tumor necrosis factor alpha; TNFRα, tumor necrosis factor alpha receptor.

It is made available under a CC-BY 4.0 International license .

# **Supplemental Digital Content**

Appendix 1. Comparison of demographic and clinical characteristics across the discovery, verification,

and validation cohorts.

		Discovery	Verification	Validation	Duralua
Number of subtrate		(PAPR)	(TREETOP)	(TREETOP)	P value
Number of subjects		1352	1251	2289	0.001
Maternal age		27	20	20	<0.001
iviedian		27	30	29	
IQR		23-32	25-33	25-33	
Unknown (n)		0	0	0	
BMI					0.005
Median		26.6	26.3	26.0	
IQR		22.7–32.6	22.6-31.0	22.3-31.2	
Unknown (n)		24	15	26	
Maternal race (n, %)					<0.001
Black		237 (17.5)	238 (19.0)	407 (17.8)	
White		981 (72.6)	778 (62.2)	1445 (63.1)	
None of the ab	ove	134 (9.9)	212 (16.9)	382 (16.7)	
Unknown (n)		0 (0.0)	23 (1.8)	55 (2.4)	
Maternal ethnicity (n,	%)				0.028
Hispanic		504 (37.3)	515 (41.2)	925 (40.4)	
Non-Hispanic		848 (62.7)	734 (58.7)	1364 (59.6)	
Unknown (n)		0 (0.0)	2 (0.2)	0 (0.0)	
Maternal education le	evel (n, %)				< 0.001
No high school	graduation	355 (26.3)	196 (15.7)	327 (14.3)	
High school de	gree/GED	656 (48.5)	579 (46.3)	1068 (46.7)	
College degree		329 (24.3)	472 (37.7)	877 (38.3)	
Unknown (n)		12 (0.9)	4 (0.3)	17 ( 0.7)	
Parity (n, %)					< 0.001
Nulliparous (P=	=0)	475 (35.1)	518 (41.4)	981 (42.9)	
Multiparous (P	≥1)	877 (64.9)	733 (58.6)	1308 (57.1)	
Unknown		0 (0.0)	0 (0.0)	0 (0.0)	
Previous PE (preterm	+ term) (n, %)				< 0.001
No		790 (90.1)	664 (90.6)	1120 (85.6)	
Yes		87 (9.9)	69 (9.4)	188 (14.4)	
Unknown		0 (0.0)	0 (0.0)	0 (0.0)	
Chronic hypertension	(n, %)				0.495
No		1264 (93.5)	1180 (94.3)	2161 (94.4)	
Yes		88 ( 6.5)	71 ( 5.7)	128 ( 5.6)	
Unknown (n)		0 (0.0)	0 (0.0)	0 (0.0)	
Pregestational diabete	es mellitus (n, %)				0.531
No		1281 (94.7)	1194 (95.4)	2165 (94.6)	
Yes		71 (5.3)	57 ( 4.6)	124 ( 5.4)	
Unknown (n)		0 (0.0)	0 (0.0)	0 (0.0)	
Gestational age at blo	od draw (d)				<0.001
Median		140	136	137	
IQR		132–147	132–141	133–141	
Unknown (n)		0 (0.0)	0 (0.0)	0 (0.0)	
Gestational age at del	ivery (d)				<0.001
Median		273	275	274	
IQR		266–278	268–281	269–280	
Unknown (n)		0 (0.0)	0 (0.0)	0 (0.0)	
Neonatal length of ho	spital stay (d)				<0.001
Median		3	2	2	
IQR		2–3	2–3	2–3	
Unknown (n)		12	6	9	
Neonatal gender (n, %	5)				0.384
Female		666 (49.3)	618 (49.4)	1134 (49.5)	

It is made available under a CC-BY 4.0 International license .

Male	686 (50.7)	632 (50.5)	1152 (50.3)	
Ambiguous	0 (0.0)	1 (0.1)	0 (0.0)	
Unknown	0 (0.0)	0 (0.0 )	3 (0.1)	

Categorical variables are shown with counts and percentages, and continuous variables are shown with medians and interquartile ranges. Comparison among the three cohorts was performed using Kruskal-Wallis or chi squared tests as appropriate. Collection of neonatal hospital stay was capped at 28 days according to the PAPR<sup>23</sup> and TREETOP<sup>24</sup> study protocols.

BMI, body mass index; IQR, interquartile range; GED, general education diploma; NA, not applicable; PE, preeclampsia; PTB, preterm birth.

It is made available under a CC-BY 4.0 International license .

Appendix 2. Validation performance of nine candidate preeclampsia classifier models. Score thresholds are specific to each classifier and differentiate subjects predicted to be at higher risk for preterm preeclampsia, defined as preeclampsia <37 weeks' gestation, from those predicted to be at lower risk. Three score thresholds distinguishing higher from lower risk were validated for each classifier. The linear relationship between the gestational age at delivery and classifier prediction was assessed by the Pearson correlation coefficient. Validation performance is reported across the nine classifiers without protein specific batch calibration.

					Pearson correlation	Pearson correlation
	AUC	1° threshold	2° threshold	3° threshold	coefficient	coefficient
Classifier	[95% CI]	P value	P value	P value	r	P value
ClinRisk3 + INHBC/SHBG	0.78 [0.73-0.84]	7.26 x 10 <sup>-13</sup>	2.69 x 10 <sup>-12</sup>	3.64 x 10 <sup>-11</sup>	-0.275	2.20 x 10 <sup>-04</sup>
ClinRisk3 + IBP4/SHBG + AFAM/PRG2	0.77 [0.71-0.83]	4.13 x 10 <sup>-12</sup>	1.30 x 10 <sup>-11</sup>	2.26 x 10 <sup>-11</sup>	-0.29	1.19 x 10 <sup>-04</sup>
ClinRisk3 + AFAM/SHBG	0.76 [0.69-0.82]	7.36 x 10 <sup>-11</sup>	7.46 x 10 <sup>-11</sup>	4.22 x 10 <sup>-13</sup>	-0.24	1.25 x 10 <sup>-03</sup>
ClinRisk3 + CD14/SHBG	0.76 [0.70-0.82]	5.27 x 10 <sup>-12</sup>	1.24 x 10 <sup>-10</sup>	3.03 x 10 <sup>-10</sup>	-0.26	4.44 x 10 <sup>-04</sup>
ClinRisk3 + IBP4/SHBG + AFAM/CSH <sup>†</sup>	0.76 [0.69-0.82]	6.04 x 10 <sup>-12</sup>	4.61 x 10 <sup>-11</sup>	4.22 x 10 <sup>-11</sup>	-0.25	9.17 x 10 <sup>-04</sup>
ClinRisk3 + IBP4/SHBG + CD14/PRG2	0.76 [0.70-0.83]	4.61 x 10 <sup>-11</sup>	2.47 x 10 <sup>-13</sup>	1.25 x 10 <sup>-11</sup>	-0.29	7.53 x 10 <sup>-05</sup>
ClinRisk3 + IBP4/SHBG + PEDF/CSH <sup>+</sup>	0.76 [0.70-0.82]	1.89 x 10 <sup>-11</sup>	1.63 x 10 <sup>-11</sup>	1.51 x 10 <sup>-11</sup>	-0.26	4.32 x 10 <sup>-04</sup>
ClinRisk3 + IBP4/SHBG + PEDF/CBPN	0.73 [0.67-0.80]	1.20 x 10 <sup>-11</sup>	2.00 x 10 <sup>-11</sup>	4.22 x 10 <sup>-10</sup>	-0.24	1.16 x 10 <sup>-03</sup>
ClinRisk3 + IBP4/SHBG + CD14/CBPN	0.72 [0.66-0.79]	1.60 x 10 <sup>-10</sup>	3.08 x 10 <sup>-11</sup>	1.28 x 10 <sup>-10</sup>	-0.25	9.96 x 10 <sup>-04</sup>

<sup>†</sup>Represents CSH1 and CSH2. The two proteins differ by one amino acid residue, which is not included in the peptide fragment measured by the predictor.

AFAM, afamin; AUC, area under the receiver operating characteristic curve; CBPN, carboxypeptidase N catalytic chain; CD14, monocyte differentiation antigen CD14; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; CSH, chorionic somatomammotropin hormone 1/2; IBP4, insulin-like growth factor-binding protein 4; PEDF, pigment epithelium-derived factor; PRG2, bone marrow proteoglycan; SHBG, sex hormone-binding globulin.

It is made available under a CC-BY 4.0 International license .

**Appendix 3.** Predictive performance of the ClinRisk3+INHBC/SHBG classifier model and a U.S. Preventive

Services Task Force<sup>35</sup> clinical risk factor-based classifier (representing standard care) for preterm

preeclampsia risk in the full validation cohort.

Cohort	Tested population	Preterm preeclampsia GA (weeks)	Cases/Total Subjects (%)	Predictor	AUC (95% CI)
Full validation cohort	All parity	<37	62/2261 (2.7%)	ClinRisk3+INHBC/SHBG	0.79 (0.74 – 0.85)
				USPSTF guidelines (standard of care)	0.68 (0.63 – 0.73)
		<34	26/2261 (1.1%)	ClinRisk3+INHBC/SHBG	0.83 (0.78 – 0.89)
	Nulliparas	<37	21/050 (2.1%)	ClinRisk3+INHBC/SHBG	0.76 (0.68 – 0.85)
			31/909 (3.1%)	USPSTF guidelines (standard of care)	0.68 (0.61-0.75)
		<34	13/969 (1.3%)	ClinRisk3+INHBC/SHBG	0.81 (0.73 – 0.90)

AUC, area under the receiver operating characteristic curve; CI, confidence interval; ClinRisk3, composite clinical variable including preeclampsia in a previous pregnancy, pregestational hypertension, and pregestational diabetes; GA, gestational age; INHBC, inhibin subunit beta C chain; SHBG, sex hormone-binding globulin.